Share Prices & Company Research

Stockbroking

AstraZeneca

Current Price 6805.00p Bid 6320.00p Ask 7091.00p Change -1.12%
Last Updated: 28/03/2020 18:45. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

Financial Highlights Year Ended 31/12/2019

Revenue
$24,384.00m
Operating Profit/Loss
$2,924.00m
Dividend yield (%)
3.00
Total dividend for year
$2.8000
Dividend cover
0.37
P/E Ratio
92.00

Stock Details

EPIC
AZN
ISIN
GB0009895292
Shares in Issue
1,312.21m
Market cap
£89,295.64m

Analyst Views (5)

Strong Buy
 
0%
Buy
 
80.00%
Hold
 
0%
Sell
 
20.00%
Strong Sell
 
0%
This information is provided by Web Financial Group (UK) Limited. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
6,805.00p
Bid Price
6,320.00p
Ask Price
7,091.00p
Volume
2,876,811
Change Today
-77.00p
% Change Today
-1.12%
Open
6,798.00p
Previous Close
6,805.00p
Intraday High
6,840.00p
Intraday Low
6,598.00p
52 Week High
7,878.00p
52 Week Low
5,644.00p
52 week high and low figures quoted above are calculated from intraday price data.

AstraZeneca News

AstraZeneca hyperkalaemia drug gets approval in Japan 26 Mar 2020 | 09:34 AstraZeneca's Lynparza gets new orphan designation in Japan 19 Mar 2020 | 13:38 Tuesday broker round-up 17 Mar 2020 | 13:08 AstraZeneca posts mixed update on lung cancer drug R&D 17 Mar 2020 | 11:10 Trump set to declare national emergency in US, freeing up funding 13 Mar 2020 | 16:57 AstraZeneca reports disappointing results from latest 'Lynparza' trial 12 Mar 2020 | 08:28 AstraZeneca bladder treatment fails to met trial endpoint 06 Mar 2020 | 07:52 Tuesday broker round-up 25 Feb 2020 | 14:07 AstraZeneca offloads 'Movantik' rights to RedHill Biopharma 25 Feb 2020 | 07:57 Thursday broker round-up 20 Feb 2020 | 14:22 Director dealings: AstraZeneca director makes share purchase 19 Feb 2020 | 16:56 Monday broker round-up 17 Feb 2020 | 14:32 London midday: Stocks steady as some analysts sound hopeful note on coronavirus 14 Feb 2020 | 12:30 AstraZeneca profit falls as costs and writedowns increase 14 Feb 2020 | 09:34 London open: Stocks little changed as traders reassess coronavirus risks 14 Feb 2020 | 08:48 Astra reports positive results from stroke, gastric cancer trials 27 Jan 2020 | 09:30 AstraZeneca sells hypertension drug rights; Ends Allergan deal 27 Jan 2020 | 08:44 Wednesday broker round-up 22 Jan 2020 | 14:30 AstraZeneca clears regulatory hurdles with 'Imfinzi' and 'Lynparza' 20 Jan 2020 | 08:11 Thursday broker round-up 16 Jan 2020 | 13:15 AstraZeneca upbeat on 'Lynparza' decision, closes 'Epanova' trial 13 Jan 2020 | 09:56 AstraZeneca clears regulatory hurdles in US and China 06 Jan 2020 | 09:40 AstraZeneca gets US approval for 'Lynparza' in pancreatic cancer 30 Dec 2019 | 08:15 AstraZeneca upbeat on approvals in China and the US 23 Dec 2019 | 07:40 Friday broker round-up 20 Dec 2019 | 13:27

Income Statement

Year End Date
31 Dec 2019
31 Dec 2018
 
$ (M)
$ (M)
Continuing Operations
Revenue
24,384.00
22,090.00
Operating Profit/Loss
2,924.00
3,387.00
Net Interest
-1,260.00
-1.28
Pre-Tax Profit
1,548.00
1,993.00
Profit After Tax from continuing operations
1,227.00
2,050.00
Discontinued Operations
Profit After Tax
n/a
n/a
Profit/Loss for the Year
1,227.00
2,050.00
Attributable to:
Equity Holders of Parent Company
1,335.00
2,155.00
Minority Interests
-108.00
-105.00
Total Dividend Paid
$2.8000
$2.8000
Retained Profit/(Loss) for the Financial Year
n/a
n/a

Earnings per Share

Year End Date
31 Dec 2019
31 Dec 2018
Basic
103.00c
170.00c
Diluted
103.00c
170.00c
Adjusted
103.00c
170.00c
Dividend per Share
$2.8000
$2.8000

Assets

Year End Date
31 Dec 2019
31 Dec 2018
 
$ (M)
$ (M)
Non-Current Assets
Property, Plant & Equipment
8,335.00
7,421.00
Intangible Assets
32,501.00
33,666.00
Investment Properties
n/a
n/a
Investments
1,459.00
922.00
Other Financial Assets
n/a
n/a
Other Non-Current Assets
3,519.00
3,051.00
Current Assets
Inventories
3,193.00
2,890.00
Trade & Other Receivables
6,046.00
5,781.00
Cash at Bank & In Hand
5,369.00
4,831.00
Current Asset Investments
n/a
n/a
Other Current Assets
955.00
2,089.00
Other Assets
n/a
n/a
Total Assets
61,377.00
60,651.00

Liabilities

Year End Date
31 Dec 2019
31 Dec 2018
 
$ (M)
$ (M)
Current Liabilities
Borrowings
2,010.00
1,754.00
Other Current Liabilities
16,107.00
14,538.00
Total Current Liabilities
18,117.00
16,292.00
Non-Current Liabilities
Borrowings
16,217.00
17,359.00
Provisions
3,331.00
3,671.00
Other Non-Current Liabilities
9,116.00
9,285.00
Total Non-Current Liabilities
28,664.00
30,315.00
Other Liabilities
n/a
n/a
Total Liabilities
46,781.00
46,607.00

Net Assets

Year End Date
31 Dec 2019
31 Dec 2018
 
$ (M)
$ (M)
Net Assets
14,596.00
14,044.00

Capital & Reserves

Year End Date
31 Dec 2019
31 Dec 2018
 
$ (M)
$ (M)
Share Capital
328.00
317.00
Share Premium Account
7,941.00
4,427.00
Other Reserves
2,046.00
2,041.00
Retained Earnings
2,812.00
5,683.00
Shareholders Funds
13,127.00
12,468.00
Minority Interests/Other Equity
1,469.00
1,576.00
Total Equity
14,596.00
14,044.00

Dividend History

Type
Ex-Dividend Date
Payment Date
Payment
2nd Interim
27 Feb 2020
30 Mar 2020
190.00¢
1st Interim
08 Aug 2019
09 Sep 2019
90.00¢
2nd Interim
28 Feb 2019
27 Mar 2019
190.00¢
1st Interim
09 Aug 2018
10 Sep 2018
90.00¢
2nd Interim
15 Feb 2018
19 Mar 2018
190.00¢
1st Interim
10 Aug 2017
11 Sep 2017
90.00¢
2nd Interim
16 Feb 2017
20 Mar 2017
190.00¢
1st Interim
11 Aug 2016
12 Sep 2016
90.00¢
2nd Interim
17 Feb 2016
21 Mar 2016
190.00¢
1st Interim
13 Aug 2015
14 Sep 2015
90.00¢
Final
03 Feb 2010
15 Mar 2010
171.00¢
Interim
05 Aug 2009
14 Sep 2009
59.00¢

Dividend Metrics

Year End Date
31 Dec 2019
31 Dec 2018
Dividend growth
n/a%
n/a%
Dividend yield
3.00%
3.80%
Dividend cover
0.37
0.61
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 26th March 2020
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.